91 participants
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-12-11
- Start Date:
- 2021-04-12
- Completion:
- 2024-12-31
Conditions
- Prostate Cancer
- mCRPC
Interventions
- DRUG
No Results Yet